Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial

OBJECTIVE: Epilepsy develops in 70 to 90% of children with tuberous sclerosis complex (TSC) and is often resistant to medication. Recently, the concept of preventive antiepileptic treatment to modify the natural history of epilepsy has been proposed. EPISTOP was a clinical trial designed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotulska, Katarzyna, Kwiatkowski, David J., Curatolo, Paolo, Weschke, Bernhard, Riney, Kate, Jansen, Floor, Feucht, Martha, Krsek, Pavel, Nabbout, Rima, Jansen, Anna C., Wojdan, Konrad, Sijko, Kamil, Głowacka‐Walas, Jagoda, Borkowska, Julita, Sadowski, Krzysztof, Domańska‐Pakieła, Dorota, Moavero, Romina, Hertzberg, Christoph, Hulshof, Hanna, Scholl, Theresa, Benova, Barbora, Aronica, Eleonora, de Ridder, Jessie, Lagae, Lieven, Jóźwiak, Sergiusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898885/
https://www.ncbi.nlm.nih.gov/pubmed/33180985
http://dx.doi.org/10.1002/ana.25956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898885/
https://www.ncbi.nlm.nih.gov/pubmed/33180985
http://dx.doi.org/10.1002/ana.25956

Ejemplares similares